Skip to content
OpenCapital
Get started

Ocular Therapeutix OCUL Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$14.5MMiss by $1.6M
EPS-$0.37Beat by $0.02
Revenue estimate$16.1M
EPS estimate-$0.39

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$13.2M
EPS estimate-$0.40

Financials

Q3 2025

Income statement

See full
Revenue$14.5M-5.7%
Gross profit$12.8M-7.9%
Operating income-$68.7M-49.3%
Net income-$69.4M-90.2%
EPS (diluted)-$0.38-72.7%

Balance sheet

See full
Cash & equivalents$344.8M-19.3%
Total debt$77.0M+2.5%
Total equity$258.2M-26.6%
Total assets$410.9M-16.2%

Cash flow

See full
Operating cash flow-$50.7M-38.7%
CapEx$6.0M+6,634%
Free cash flow-$56.7M-54.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.03B+41.0%
Enterprise value$1.77B+62.0%
P/S36.5×+13.0×

Profitability

See full
Gross margin88.9%-1.7pp
Operating margin-449.7%+9,735pp
Net margin-447.6%+611pp
FCF margin-357.5%+1,907pp

Returns & leverage

See full
Return on equity-81.8%-11.0pp
Debt / equity0.3×+0.1×
Current ratio7.9×-5.2×

Segments

By segment

See full
Single Reportable$14.5M-5.7%

Versus estimates

Revenue

Q1 2026$10.8MMiss by $1.9MQ4 2025$13.3MMiss by $2.9M
Q3 2025$14.5MMiss by $1.6M
Q2 2025$13.5MMiss by $1.1MQ1 2025$10.6MMiss by $2.5MQ4 2024$17.1MMiss by $29.8K

Diluted EPS

Q1 2026-$0.41Miss by $0.09Q4 2025-$0.29Beat by $0.04
Q3 2025-$0.37Beat by $0.02
Q2 2025-$0.39Miss by $0.04Q1 2025-$0.37Miss by $0.08Q4 2024-$0.29Miss by $0.05

Ask the moment Ocular Therapeutix reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Ocular Therapeutix report Q3 2025 earnings?
Ocular Therapeutix (OCUL) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Ocular Therapeutix's Q3 2025 revenue and EPS?
Ocular Therapeutix reported revenue of $14.5M and eps of $-0.37 for Q3 2025.
Did Ocular Therapeutix beat estimates in Q3 2025?
Revenue missed the consensus estimate of $16.1M by $1.6M. EPS beat the consensus estimate of $-0.39 by $0.02.
How did Ocular Therapeutix's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 5.7% from $15.4M a year earlier and eps declined 42.3% from $-0.26.
Where can I find Ocular Therapeutix's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-105914) and the 10-Q periodic report (0001104659-25-105919) directly on SEC EDGAR. The filing index links above go to sec.gov.